research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
On 27 October, the Catalan parliament voted in a secret ballot to unilaterally declare independence from Spain, with most deputies of the opposition boycotting a vote considered illegal for violating the decisions of the Constitutional Court of Spain, as the lawyers of the Parliament of Catalonia warned. As a result, the government of Spain invoked the Constitution to remove the regional authorities and enforce direct rule the next day, with a regional election being subsequently called for 21 December 2017 to elect a new Parliament of Catalonia. Puigdemont and part of his cabinet fled to Belgium after being ousted, as the Spanish Attorney General pressed for charges of sedition, rebellion and misuse of public funds against them. The trial of Catalonia independence leaders began on 12 February 2019 in the Supreme Court of Spain, in which 12 people were tried, including the previous vice president Oriol Junqueras of the regional government and most of the cabinet as well as political activists Jordi Sànchez and Jordi Cuixart and the former speaker of the Parliament of Catalonia Carme Forcadell. Nine of the 12 accused received prison sentences for the crimes of sedition; of them, four were also found guilty of misuse of public funds. Their sentences ranged from 9 to 13 years. The remaining three accused were found guilty of disobedience and were sentenced to pay a fine but received no prison term. The court dismissed the charges of rebellion. The verdict delivered by the Supreme Court sparked multiple protests across the region.
=== GMod Tower === In July 2009, four developers working under the name "PixelTail Games" opened a Garry's Mod server called GMod Tower. GMod Tower was a network of servers, designed as a social media platform for users to play minigames with friends and socialise in a hub area. Within hours of the server's opening, the website for GMod Tower reached two million views. GMod Tower temporarily shut down between January and April 2012. PixelTail Games later expanded GMod Tower into Tower Unite, a standalone game that replaced GMod Tower upon its early access release in April 2016.
(CH2CH2)O + RONa → RO–CH2CH2–O−Na+ RO–CH2CH2–O−Na+ + n (CH2CH2)O → RO–(CH2CH2–O)n–CH2CH2–O−Na+ RO–(CH2CH2–O)n–CH2CH2–O−Na+ → RO–(CH2CH2–O)n–CH=CH2 + NaOH RO–(CH2CH2–O)n–CH2CH2–O−Na+ + H2O → RO–(CH2CH2–O)(n+1)OH + NaOH
Sources: en.wikipedia.org
The British Embassy in Pyongyang was closed temporarily from 27 May and all diplomatic staff left the country. According to a statement from the British Foreign Office, this was due to restrictions on entry to the country, making it a challenge to rotate staff and sustain the operation of the Embassy. On 19 June, an update to the WHO from the Ministry of Public Health affirmed that all the educational institutions in the country were now open. The underground network that assists defectors in escaping North Korea was reported as being almost unable to operate amidst the strict controls implemented to stop the virus, and defection attempts were largely suspended. Defection rates had been declining already, probably due to increased security under the administrations of Kim Jong Un in North Korea and Xi Jinping in China. Between the start of April and end of June 2020, only 12 North Korean defectors entered South Korea, compared with 320 during the same period in 2019.
=== Elsewhere === Benjamin Franklin was the first American to mention tofu, in a 1770 letter to John Bartram. Franklin, who encountered it during a trip to London, included a few soybeans and referred to it as "cheese" from China. In 1770, Franklin also corresponded with James Flint on the subject of how the Chinese converted callivances (soybeans) into tofu. Flint's writing "Towfu" in his letter is the earliest documented use of "tofu" in the English language. The first tofu company in the United States was established in 1878. In 1908, Li Yuying, a Chinese anarchist and a vegetarian with a French degree in agriculture and biology, opened a soy factory, the Usine de la Caséo-Sojaïne. This was the world's first soy dairy and the first factory in France to manufacture and sell beancurd. However, tofu was not well known to most Westerners before the middle of the 20th century, when it was popularized in the United States by William Shurtleff and Akiko Aoyagi (The Book of Tofu, 1975).
=== Horizontal plate filters === Horizontal plate filter paper is commonly utilized in industrial processing. Filter paper typically is designed to fit the manufacturers specifications. Absolute micron retention can range from 1–100 microns but Diatomaceous earth is commonly used with filter paper to obtain sub-micron filtration. Activated carbon or other filter aids can be used with the filter paper to form a filter cake to achieve specific results. Filter paper can be impregnated with DE or activated carbon.
Sources: en.wikipedia.org
The carbonyl groups of reducing sugars react with the amino groups of amino acids in the Maillard reaction, a complex series of reactions that occurs when cooking food. Maillard reaction products (MRPs) are diverse; some are beneficial to human health, while others are toxic. However, the overall effect of the Maillard reaction is to decrease the nutritional value of food. One example of a toxic product of the Maillard reaction is acrylamide, a neurotoxin and possible carcinogen that is formed from free asparagine and reducing sugars when cooking starchy foods at high temperatures (above 120 °C). However, evidence from epidemiological studies suggest that dietary acrylamide is unlikely to raise the risk of people developing cancer.
=== DoorDash lawsuit (2015) === On November 6, 2015, In-N-Out filed a lawsuit against food delivery startup DoorDash, claiming trademark infringement. Two months later, the lawsuit was settled out of court in a confidential settlement. DoorDash no longer delivers food from In-N-Out Burger.
=== Blood supply === The liver gets its blood supply from the hepatic portal vein and hepatic arteries. The hepatic portal vein delivers around 75% of the liver's blood supply and carries venous blood drained from the spleen, gastrointestinal tract, and its associated organs. The hepatic arteries supply arterial blood to the liver, accounting for the remaining quarter of its blood flow. Oxygen is provided from both sources; about half of the liver's oxygen demand is met by the hepatic portal vein, and half is met by the hepatic arteries. The hepatic artery also has both alpha- and beta-adrenergic receptors; therefore, flow through the artery is controlled, in part, by the splanchnic nerves of the autonomic nervous system. Blood flows through the liver sinusoids and empties into the central vein of each lobule. The central veins coalesce into hepatic veins, which leave the liver and drain into the inferior vena cava.
== See also == AXIN1 GSK-3 Management of hair loss Wingless localisation element 3 (WLE3) WNT1-inducible-signaling pathway protein 1 (WISP1) WNT1-inducible-signaling pathway protein 2 (WISP2) WNT1-inducible-signaling pathway protein 3 (WISP3)
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.